The leadership team at Corium brings together industry-leading experts in drug development, manufacturing, and commercialization who are dedicated to doing more for our partners and patients.
Todd Smith, CEO of Corium, has built his career on business and organizational transformation across the pharmaceutical and medical device industries. He is known for his leadership and innovative, creative and strategic approach to business, which have resulted in consistent revenue and value growth, evidenced by $1 billion+ capital raised, more than 25 product launches, and 100+ BD/M&A deals. In addition, he has founded more than 10 healthcare companies.
Prior to Corium, Todd has held leadership positions at multiple pharmaceutical companies, including CEO of Valinor, CEO of Iroko Pharmaceuticals, Zyla Life Sciences, and Assertio Therapeutics, as well as Chief Commercial Officer and Head of BD at Horizon Therapeutics and at Tolmar Pharma.
Todd serves on several boards, including BVI Medical and Vault Pharma, and holds a B.A. in political science from Norwich University.
Ben is a highly accomplished and dynamic leader with 15 years of experience successfully launching companies, transforming performance, and accelerating growth within the healthcare and pharmaceutical industries.
Having held numerous President, CEO, and Chairman roles at companies including Iroko Pharmaceuticals, Apollo Care, and Valinor Pharma, Ben has led many transformative company turnarounds in the pharmaceutical industry. Previously, Ben was President of Commercial and Finance at Valinor Pharma where he oversaw 150% revenue growth in less than 12 months, leading to sale of Valinor Pharma to Grünenthal GmbH. Prior to that Ben was General Manager of the Primary Care business unit and led Analytics at Horizon Therapeutics. His strategic vision and transformative leadership have resulted in commercial improvements of 5-15x. Ben has founded more than ten healthcare companies, pioneered numerous first-to-market technologies/tools and innovative commercial models, vetted hundreds of business development deals, and led acquisitions of several pharma companies and products.
Ben serves on multiple boards across the pharmaceutical, technology, and nonprofit sectors. He holds an MBA, a Master of Engineering Management, and a B.S. in mechanical engineering, each from Northwestern University.
Blythe J. Buchanan is a regulatory affairs leader with over 20 years of experience in Fortune 500 and privately held biopharmaceutical companies. As Vice President, Head of Regulatory Affairs at Corium, she oversees regulatory strategy, compliance, CMC and operations across the corporate product portfolio. Her leadership has driven key regulatory successes, including multiple CMC approvals and international collaborations.
Prior to Corium, Blythe held senior roles at Biogen, where she led global regulatory advertising and promotion strategies, contributing to the approval and launch of several new therapies as well as the advancement of the overall function globally. She is known for her strategic, business-focused approach to regulatory affairs, driving successful commercialization and compliance outcomes.
Blythe holds a BA in Psychology/Sociology from Wesleyan College and is a member of the Regulatory Affairs Professional Society and other industry organizations.
Jeremy Burchardt brings 25 years of experience in technical operations and manufacturing, with the last 20 years in the biopharmaceutical industry. As Corium’s Head of Technical Operations, Jeremy establishes the strategy and manages the end-to-end operations across supply chain, quality, and external manufacturing for both clinical and commercial programs. Prior to joining Corium in 2023, Jeremy served as Vice President of Supply Chain and Program Management for Corium’s contract development and manufacturing partner, Corium Innovations. Over the course of his tenure at Corium Innovations, he held positions of increasing responsibility in supply chain and program management, playing a critical role in moving several products from development to commercial launch. Jeremy holds a bachelor’s degree in Business Management and a master’s degree in Regulatory Affairs.
Kathy Francini joined Corium in March 2020 as Senior Director of Human Resources for R&D and Commercial, bringing over 20 years of experience in the life sciences industry. She now serves as Head of Human Resources, where she leads Corium’s people strategy and communication initiatives, ensuring alignment with the company’s strategic business goals.
Throughout her career, Kathy has held key leadership roles in human resources, including Head of Commercial HR and Head of Global Talent Acquisition at Shire, as well as talent acquisition leadership positions at Ironwood Pharmaceuticals and Sepracor/Sunovion. She has extensive experience managing HR functions through product launches, mergers, acquisitions and periods of rapid growth and transformation.
Kathy holds a degree in Chemistry and Marketing from Clarkson University.
Tim Moore joined Corium in 2021, bringing nearly 20 years of legal expertise across Fortune 200 companies, private practice, and public service. As Vice President, Head of Legal & Compliance, Secretary, Tim leads Corium’s legal and compliance functions, which he has been instrumental in building. Under his leadership, his team played a key role in Corium’s transition to commercialization and the launch of Corium’s first FDA-approved product, AZSTARYS.
Prior to joining Corium, Tim served as Assistant General Counsel at BD, overseeing two global platforms—BD Home Care and BD Technologies & Innovation. He was also a vital member of BD Home Care’s management team, guiding the business through the challenges of the COVID-19 pandemic and enabling its evolution into a global platform. Earlier in his career, Tim practiced law at Shook, Hardy & Bacon, specializing in product liability, commercial litigation, government litigation, and compliance counseling. He began his career in public service as an Assistant State Attorney in Miami and later as a Special Assistant U.S. Attorney in the U.S. Attorney’s Office for the Southern District of Florida.
Dr. Charles Oh joined Corium in 2020 with more than 15 years of experience in the pharmaceutical/biotech industry. He has an established track record of industry accomplishments for achieving regulatory approval of multiple drugs and medical devices in North America and Europe, executing medical affairs strategies in support of commercial products, and leading scientific evaluations of business development opportunities. His industry experience encompasses a wide range of therapeutic areas, including pain management, cardiology, and neurology.
As chief medical officer at Corium, Charles drives the execution of clinical development programs, leads medical affairs to support commercial products, and builds the company’s product pipeline. Prior to joining Corium, Charles served as Senior Vice President, Clinical Development at Acorda Therapeutics. Prior to that, he held roles of increasing responsibility and leadership at Johnson & Johnson and Purdue Pharma. Dr. Oh received his medical degree from Washington University in St. Louis and subsequently trained in internal medicine and cardiology. He also received an M.B.A. from the University of North Carolina at Chapel Hill and a B.S. in Biology from the University of Miami (FL).
